A new method for the labelling of proteins with radioactive arsenic isotopes

M. Jennewein, A. Hermanne, R. P. Mason, P. E. Thorpe, F. Rösch

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Radioarsenic labelled radiopharmaceuticals could be a valuable asset to positron emission tomography. In particular, the long half-lives of 72As (T1 / 2 = 26 h) and 74As (T1 / 2 = 17.8 d) allow to investigate slow physiological or metabolical processes, like the enrichment and distribution of monoclonal antibodies (mab) in tumour tissue. In this work, a new method for the labelling of proteins with various radioactive arsenic isotopes was developed. For this purpose, two proteins, namely a chimeric IgG3 monoclonal antibody, ch3G4, directed against anionic phospholipids, and Rituxan (Rituximab), were labelled as a proof of principle with no-carrier-added radioarsenic isotopes (74As and 77As). The developed labelling chemistry gives high yields (>99.9%), is reliable and could easily be transferred to automated labelling systems in a clinical environment. At least for the mab used in this work, this route of radioarsenic labelling does not affect the immunoreactivity of the product. The arsenic label stays stable for up to 72 h at the molecular mass of the monoclonal antibody, which is in particular relevant to follow the pharmacology and pharmacokinetics of the labelled mab for several days.

Original languageEnglish (US)
Pages (from-to)512-517
Number of pages6
JournalNuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
Volume569
Issue number2 SPEC. ISS.
DOIs
StatePublished - Dec 20 2006

    Fingerprint

Keywords

  • Labelled antibodies
  • Protein labelling
  • Radioactive arsenic

ASJC Scopus subject areas

  • Nuclear and High Energy Physics
  • Instrumentation

Cite this